James S. Blachly

James S. Blachly

Auto-generated profile, based on publicly available information

James S. Blachly

The Ohio State University, Columbus, Ohio, United States

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 December 2014 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
RGRamiro Garzon
Ramiro Garzon
Stefano VoliniaStefano Volinia
Stefano Volinia
DPDimitrios Papaioannou
Dimitrios Papaioannou
DNDeedra Nicolet
Deedra Nicolet
JKJessica Kohlschmidt
Jessica Kohlschmidt
CBClara D. Bloomfield
Clara D. Bloomfield
Significance: Long noncoding RNAs (lncRNAs) are involved in numerous biological roles including epigenetic regulation, apoptosis, and cell cycle. Whereas lncRNAs contribute to epigenetic gene regulation, metastasis, and prognosis in solid tumors, their role in acute myeloid leukemia (AML) has not been hitherto reported. Here, we show that lncRNA expression profiles are associated with recurrent mutations, clinical features, and outcome in AML. A fraction of these lncRNAs may have a functional role in leukemogenesis. Furthermore, lncRNAs could be used as biomarkers for outcome in AML. The identification of patients likely to achieve complete remission with standard therapy alone, based on lncRNA expression, is a significant advance potentially sparing such patients from other toxicities and focusing investigational approaches on postremission studies.

28 August 2025 in Blood
Verified
Journal Article
Open access
MAMartha L. Arellano
Martha L. Arellano
MTMichael J. Thirman
Michael J. Thirman
JDJohn F. DiPersio
John F. DiPersio
MHMael Heiblig
Mael Heiblig
ESEytan M. Stein
Eytan M. Stein
JBJames S. Blachly
James S. Blachly
The prognosis for relapsed or refractory (R/R) nucleophosmin 1–mutated (NPM1m) acute myeloid leukemia (AML) is poor and represents an urgent unmet medical need. Revumenib, a potent, selective menin inhibitor, was recently approved for the treatment of R/R acute leukemia with a KMT2A translocation in patients aged ≥1 year based on results from the phase 1/2 AUGMENT-101 study. Here, we present results from patients with R/R NPM1m AML enrolled in the phase 2 portion of AUGMENT-101. Enrolled patients received revumenib with or without a strong CYP3A4 inhibitor every 12 hours in 28-day cycles. Primary end points were rate of complete remission (CR) or CR with partial hematologic recovery (CRh; CR + CRh), safety, and tolerability. Secondary end points included overall response rate (ORR) and duration of response. As of 18 September 2024, 84 patients received ≥1 dose of revumenib. Median age was 63 years; 1 patient was aged <18 years. The protocol-defined, efficacy-evaluable population for the primary analysis included 64 adult patients (≥3 previous lines of therapy, 35.9%; previous venetoclax, 75.0%). The CR + CRh rate was 23.4% (1-sided P = .0014); the ORR was 46.9%. Median duration of CR + CRh was 4.7 months. Of 30 responders, 5 (16.7%) proceeded to hematopoietic stem cell transplant (HSCT) and 3 resumed revumenib after HSCT. Treatment-related adverse events led to treatment discontinuation in 4 patients (4.8%). Revumenib demonstrated clinically meaningful responses in this heavily pretreated, older population with NPM1m AML, including remissions that enabled HSCT. The safety profile of revumenib was consistent with previously reported results. This trial was registered at www.clinicaltrials.gov as #NCT04065399.

6 August 2014 in British Journal of Haematology
Verified
Journal Article
Closed access
PDF file
JBJames S. Blachly
James S. Blachly
RBrobert baiocchi
robert baiocchi

27 May 2020 in Leukemia
Verified
Journal Article
Closed access
PDF file
AEAnn-Kathrin Eisfeld
Ann-Kathrin Eisfeld
JKJessica Kohlschmidt
Jessica Kohlschmidt
AMAlice Mims
Alice Mims
DNDeedra Nicolet
Deedra Nicolet
CWChristopher J. Walker
Christopher J. Walker
CBClara D. Bloomfield
Clara D. Bloomfield

23 February 2023 in Leukemia
Verified
Journal Article
Open access
PDF file
KMKrzysztof Mrózek
Krzysztof Mrózek
JKJessica Kohlschmidt
Jessica Kohlschmidt
JBJames S. Blachly
James S. Blachly
DNDeedra Nicolet
Deedra Nicolet
ACAndrew J. Carroll
Andrew J. Carroll
AEAnn-Kathrin Eisfeld
Ann-Kathrin Eisfeld
Recently, the European LeukemiaNet (ELN) revised its genetic-risk classification of acute myeloid leukemia (AML). We categorized 1637 adults with AML treated with cytarabine/anthracycline regimens according to the 2022 and 2017 ELN classifications. Compared with the 2017 ELN classification, 2022 favorable group decreased from 40% to 35% and adverse group increased from 37% to 41% of patients. The 2022 genetic-risk groups seemed to accurately reflect treatment outcomes in all patients and patients aged <60 years, but in patients aged ≥60 years, relapse rates, disease-free (DFS) and overall (OS) survival were not significantly different between intermediate and adverse groups. In younger African-American patients, DFS and OS did not differ between intermediate-risk and adverse-risk patients nor did DFS between favorable and intermediate groups. In Hispanic patients, DFS and OS did not differ between favorable and intermediate groups. Outcome prediction abilities of 2022 and 2017 ELN classifications were similar. Among favorable-risk patients, myelodysplasia-related mutations did not affect patients with CEBPAbZIP mutations or core-binding factor AML, but changed risk assignment of NPM1-mutated/FLT3-ITD-negative patients to intermediate. NPM1-mutated patients with adverse-risk cytogenetic abnormalities were closer prognostically to the intermediate than adverse group. Our analyses both confirm and challenge prognostic significance of some of the newly added markers.

8 February 2019 in Leukemia
Verified
Journal Article
Closed access
PDF file
KMKrzysztof Mrózek
Krzysztof Mrózek
AEAnn-Kathrin Eisfeld
Ann-Kathrin Eisfeld
JKJessica Kohlschmidt
Jessica Kohlschmidt
ACAndrew J. Carroll
Andrew J. Carroll
CWChristopher J. Walker
Christopher J. Walker
CBClara D. Bloomfield
Clara D. Bloomfield